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Abstract
New York City health officials announced on February 11, 2005 that a patient rapidly developed
full-blown AIDS shortly after being diagnosed with a rare, drug-resistant strain of HIV-1. The New
York City Department of Health issued an alert to all hospitals and doctors and a press conference
was held to announce the emergence of an aggressive HIV-1 strain that may be difficult to treat and
that appears to trigger rapid progression to AIDS. Is the panic justified?
The two phenomena of rapid disease progression and
multi-drug resistance, which are combined in the aggres-
sive HIV-1 strain, are not unique. HIV-1 causes a persistent
infection and this virus is generally not a fast killer. Within
the Amsterdam Cohort Studies on HIV-AIDS, it takes on
average 8.3 years from the time a person is first infected
with HIV-1 for AIDS to develop, and another 17 months
from AIDS to death [1]. However, the length of the incu-
bation period varies from 2 months to more than 20
years. Cases where it takes much shorter are not uncom-
mon (rapid-progressors), and likewise there is a signifi-
cant group of socalled long-term non-progressors [2-5].
There seems uncertainty about the actual date of infection
of the New York individual, such that AIDS may actually
not have developed within 2 to 3 months, but rather
within 20 months, which makes this case less exotic.
Transmission of a drug-resistant HIV-1 variant is not
uncommon either [6,7]. The number of cases have
remained relatively small, but may be on the rise due to
an increase in therapy failures [8]. The New York virus
appeared resistant to three classes of antivirals (the
Reverse Transcriptase inhibitors; nucleoside and non-
nucleoside drugs, as well as Protease inhibitors), but this
is not unexpected either in the era of combination-therapy
in which therapy failure will usually mean the emergence
of multi-drug resistant HIV-1 variants.
Drug-resistant HIV-1 variants usually have reduced repli-
cation capacity compared to a wild-type virus due to the
mutations in the Reverse Transcriptase and Protease
enzymes [9]. This loss in replication fitness may be even
larger for a multi-drug resistant virus [10]. How does this
relate to the aggressive disease course? More research is
needed to resolve this issue. First, it is not always true that
the acquisition of drug-resistance mutations causes a fit-
ness loss. Even in case a loss is apparent, the virus may
select compensatory changes over time, and the end result
may in fact be a virus variant with increased replication fit-
ness [11]. Second, one can only link a particular patho-
genicity phenotype to a virus strain when a distinct disease
pattern is seen in multiple infected persons. When an iso-
lated case is discussed, it is equally possible that the par-
ticular disease pattern is not due to the virus, but rather
due to a special property of the infected human host. Per-
son-to-person variation in the immune system or other
factors that interact with HIV-1 (receptors, innate immune
factors etc) can greatly influence disease progression [12].
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Overall, this case seems relatively rare but not necessarily
alarming. Increased attention is not necessarily bad, but
press conferences should be reserved for situations when
a cluster of such transmissions is apparent. The current
hype about super aggressive HIV-1 strains seems
unfounded.
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